ABBREVIATIONS
Antibody (Ab), acetonitrile (ACN), alkaline phosphatase (AKP), amniotic fluid (AF), DepletionSeparation-Enrichment (DSE), fetal growth restriction (FGR), Free Flow Electrophoresis (FFE), insulin-like growth factor-I (IGF-I), insulin-like growth factor binding protein-1 (IGFBP-1), phosphoisoforms (p-isoforms), recombinant human IGF-I (rIGF-I), titanium dioxide (TiO 2 ), trifluoroacetic acid (TFA).
INTRODUCTION
Insulin-like growth factor (IGF) axis plays an important role in human fetal growth and development. Insulin-like growth factor binding protein-1 (IGFBP-1) is a major insulin-like growth factor-I (IGF-I) binding protein in amniotic fluid (AF) (1, 2) . The physiological role of IGFBP-1 is considered to be highly dependent on differential phosphorylation (6) (7) (8) . Phosphorylation of IGFBP-1 increases its affinity for IGF-I, suggesting that IGFBP-1 may modulate the action of IGF-I, specifically with respect to fetal and placental growth (2) .
AF is a dynamic and complex biofluid and reflects the physiological status of the developing fetus (9). Fetal growth restriction (FGR) is a condition in which a fetus is unable to achieve its genetically determined potential size. The concentration of total IGFBP-1 is increased in FGR pregnancies (10-13). Multiple phosphorylated species of IGFBP-1 have been detected during healthy pregnancy, both in maternal circulation and AF throughout gestation (1, 14, 15) . Several studies have considered the clinical implications of IGFBP-1 phosphorylation focusing on correlating variable ratios of high to low concentrations of IGFBP-1 phosphoisoforms with FGR (5, 7, (16) (17) (18) . Although phosphorylation of IGFBP-1 has since been suggested to be critical, the predictive or functional value of IGFBP-1 phosphorylation in FGR is still not clear. The inconsistency in measurements of variable degrees of IGFBP-1 phosphorylation by ELISAs has resulted in inconclusive findings (19) .
IGFBP-1 phosphoisoforms have been isolated and characterized earlier using conventional methods (1, 14, 15) . IGFBP-1, although relatively abundant in AF, still represents less than 0.01% of the total protein content (20) . With restricted volumes available from clinical samples, isolation of functional IGFBP-1 phosphoisoforms using traditional approaches (14, 21, 22 ) is challenging. Our goal is to obtain a comprehensive understanding of the clinical and functional implications of IGFBP-1 phosphorylation in human FGR pregnancies. We developed an efficient, reproducible and entirely liquid-based native IEF separation technology based on Free Flow Electrophoresis (FFE) (23) to facilitate characterization of both the state of phosphorylation and IGF-I binding kinetics of variably phosphorylated IGFBP-1 isoforms in a clinical sample. As a prerequisite to application of this approach clinically, we evaluated representative AF samples to determine whether or not differential patterns of IGFBP-1 phosphorylation exist in FGR, and whether these changes could be attributed to attenuation of IGF-I affinity in the disease.
MATERIALS AND METHODS
FFE reagents were obtained from BD Diagnostics (Munich, Germany) as BD™ FFE Kits, IEF Native Depletion-Separation-Enrichment (DSE), separation range pH 3-10, and IEF Native pH 4-6. for IGFBP-1 was from Diagnostic Systems Labs (Webster, TX) and Titansphere TiO (Titanium dioxide (TiO 2 )) from GL Sciences Inc. (Tokyo, Japan). Biotin labeling for rIGF-I was performed using Biotin EZ link NHC-LC (Pierce, Rockford, IL). BIAcore analysis was performed using the BIAcore X instrument (BIAcore, Inc., Piscataway, NJ).
Sample collection
The AF sample used in FFE separation was obtained at delivery from a healthy pregnant woman for which no consent was necessary. Other samples used in this study involved AF from FGR pregnancies and gestational age matched controls (n=6 each), for which consent were obtained from the donors at the time of delivery as described previously (24). All AF samples were collected applying a protease inhibitor cocktail. An aliquot of sample used in FFE was also collected without protease inhibitors to test the stability of IGFBP-1. All samples were filtered, centrifuged and flashfrozen at -80°C until used.
Sample preparation for FFE separation
The AF sample was thawed and centrifuged (Becker centrifuge JA 10 Rotor) at 8000 rpm (both at 4°C) to remove any debris. Prior to FFE separation, IGFBP-1 in AF was isolated using a salting out procedure (25) by adding solid ammonium sulphate (0-75% saturation) to the clarified AF sample.
The sample was then centrifuged at 13000 rpm for 1 hr (Beckman model J2-21 centrifuge, JA 20 Rotor). The pellet was collected and dissolved in 20 mM NaPO 4 buffer, pH 7.0. Desalting of the samples was performed by dialysis (12-14000 MWCO, Spectrum labs Inc., Canada) using the same buffer (20 mM NaPO 4 buffer, pH 7.0) at 4 °C, followed by distilled water for additional 48 hrs. The resulting sample was spun at 13000 rpm and the clear supernatant consisting of IGFBP-1 (referred as the enriched IGFBP-1) was stored at -80°C until use. Total protein concentration was determined using the BCA protein assay kit (Pierce, Rockford, IL).
Free Flow Electrophoresis
FFE separations were conducted in the IEF mode (IEF-FFE) using a BD™ FFE System* (BD Diagnostics, Munich, Germany) as described previously (26). Separation of proteins in the enriched AF sample was performed under two different conditions using either the FFE Kit IEF Native DSE, for lower resolution separation across the pH range of 3 to 10, or the FFE Kit IEF Native pH 4-6, for a narrow range pH gradient providing a higher resolution separation ( Fig. 2 i and ii) . In case of the DSE protocol, the media contained 10 % glycerol in aqueous solution in addition to the ampholytes used to create the pH gradient. The FFE separation was performed according to the manufacturer's protocols. In brief, electrolyte anode circuit was 100 mM H 2 SO 4 and cathode circuit was 100 mM and NaOH. The flow rates for the separation media were set at 120 mL/hr and for delivering the sample the rate was 3 mL/hr. A Tecan (Maennedorf, Switzerland) liquid handling system equipped with a pH electrode was used to measure the pH value of each fraction. After FFE equilibration and pI marker test, the enriched AF sample (6 mg total protein) was diluted 10x in the separation medium and the sample was infused into the chamber for IEF-FFE. Electrophoresis was performed at 10°C with a constant voltage (400 V). The separated sample was collected (3.5 mL/fraction) to a 96-well plate with a separation time of 1.5 hr.
Alternatively, FFE separation was performed for a narrow range separation of proteins using an IEF gradient from pH 4 to 6. The separation media, in addition to other constituents as described for the DSE protocol, contained 0.2 % hydroxypropyl methyl cellulose. Flow rates used were 60 mL/hr and 1 mL/hr, for medium and sample, respectively, to provide a separation of 4 mg protein/hr. In the narrow range FFE separation, AF (20 mg protein) was diluted 5x prior to separation in order to avoid precipitation in the separation chamber. Electrophoresis was performed at 10°C using 1350 V.
Furthermore, to avoid degradation of the separated samples, the FFE fractions were collected into a plates prefilled with 500 μL HBS EP buffer (10 mM HEPES, 150 mM NaCl, 3.4 mM EDTA, 0.005% surfactant P20, pH 7.4 ) per mL FFE fraction.
Of the total fractions (n=96) collected from FFE separations, selected fractions between A5 to C10 (from the 96 well plate) were analyzed for total protein separation by SDS PAGE. The total IGFBP-1 concentrations in FFE fractions E5 to B7 were analyzed by ELISA (19) . FFE fractions corresponding to pH 4.2-5.1 were selected for detection of IGFBP-1 by Western immunoblotting. 
SDS PAGE and Western immunoblot analysis

Native gel electrophoresis and ligand blot analysis
For separation of IGFBP-1 in the native state, all samples were prepared for 1-D gels using the running buffer (50mM Tris HCl pH 6.8, 25% glycerol, 1% NP-40 and 0.005% Bromophenol blue).
Proteins transferred on to PVDF membrane (Roche) were used for IGFBP-1 immunoblot analysis using Mab 6303. Additionally, ligand blot analysis was performed using biotin labeled rIGF-I (10 ng/mL). IGF binding proteins were detected by using HRP conjugated Strepavidin (1:1000 dilution) and the ECL Plus Reagent kit.
BIAcore Biosensor Interaction using Surface Plasmon Resonance (SPR) analysis
The interaction of IGFBP-1 with IGF-I was determined using BIAcore X instrument employing CM5™ sensor chip overlaid with two flow cells. For immobilization, rIGF-I (10 mg/mL) was applied to the sample cell as per manufacturer's protocol following amine coupling while the second flow cell was used as reference. Regeneration of the chip was performed using 30 μL of 10 mM glycine-HCl buffer, pH 2.0. Samples were obtained from two sets of FFE fractions. The unfractionated enriched AF was used for comparison. The kinetic measurements were performed in triplicate using a set of three dilutions. All FFE fractions used were desalted and concentrated 10x and frozen at -20°C until further use. Various concentrations of analyte (IGFBP-1) were injected for a 60 sec association phase in both reference and sample cells at 50 μL/min.
Data analysis
All binding curves were corrected for background by the subtraction of the signal obtained from the reference cell. Representative curves were generated for the association and the dissociation phases using the BIAevaluation software version 3.0 as per 1:1 Langmuir binding model to fit kinetics (BIAcore). The data are represented as mean of three independent runs with SD.
Phosphorylation of IGFBP-1 using MS:
In-solution digestion
The FFE fractions were selected, and aliquots with equal amount of IGFBP-1 were desalted and buffer exchanged using 10KDa MWCO Centricon tubes at 4ºC with ammonium bicarbonate buffer, pH 8.0. The reduction and alkylation was carried out by treating samples (200 ng IGFBP-1) with 10 mM dithiothreitol followed by 100 mM iodoacetamide. Subsequently, proteins were digested first with Asp-N endoproteinase (Sigma) (25 ng/µL), at 37°C overnight, and then with sequencing grade trypsin (12.5 ng/µL) (Promega, Madison, WI) at 37°C overnight. Digested samples were dried and stored at -80ºC.
Enrichment of IGFBP-1 phosphopeptides using Titanium dioxide (TiO 2 )
IGFBP-1 phosphopeptides in the digested samples were enriched using TiO 2 particles. In brief, the pellet with phosphopeptides were dissolved in 20 μL loading buffer (80% acetonitrile (ACN), 1% trifluoroacetic acid (TFA) and incubated with 1 μL of TiO 2 slurry (5 μm, 1 mg, 50% ACN) for 20 min at RT on a shaker. The solution and TiO 2 particles were transferred to a pipette tip to which a piece of filter paper was inserted at its end to serve as a frit. The tip was placed in a microcentrifuge tube and centrifuged for 5 min. The particles were washed using 20 μL loading buffer (50 mg/mL of dihydroxybenzoic acid and 0.2% TFA in 40% ACN). The phosphopeptides were eluted using 20 μL buffer (5% ammonium hydroxide, pH 11.0). To the receiving tube, 5 µL of 5% TFA was added prior to eluting the bound phosphopeptides. The samples were dried and reconstituted in 0.1% formic acid in water or in 50 mM EDTA in water prior to LC-MS or LC-MS/MS analysis. For the samples that were used in LC-MS analysis.
IGFBP-1 phospho-residue identification by MS
The TiO 
RESULTS
Assessment of IGFBP-1 in ammonium sulphate fractionated AF
AF shares the distinctive characteristics of human biofluids, such as the high dynamic range in protein abundance and high salt concentration. Salting out using ammonium sulphate fractionation (0-75%) was essential for removal of some interfering proteins and high salt concentration in AF prior to FFE separation. Rather than conventional albumin depletion (28), the salting out procedure proved to be efficient in elimination of albumin to minimize masking effects during FFE separation.
Based on the M r marker, although albumin (55-60 KDa band) was still detectable in the concentrated sample (Fig. 1 a, Lane 2) , the relative intensity of the band (30 kDa) corresponding to IGFBP-1 was nonetheless increased. Immunoblot analysis using the crude and the enriched AF samples ( Fig. 1 b, Lanes 1 and 2) confirmed the 30 kDa band as IGFBP-1. The sample also showed an enhanced band (20 kDa) corresponding to the proteolyzed IGFBP-1 fragment. In order to monitor the stability of IGFBP-1, AF sample (100 ng IGFBP-1) collected without protease inhibitors as described earlier was incubated at 4°C for up to 30 hrs. The samples with and without protease inhibitors were analyzed by immunoblot analysis using Mab 6303. The AF sample without protease inhibitors showed degradation (data not shown), while the sample with inhibitors resulted in only one additional band shown by an arrow (20 kDa) (Fig. 1b) , suggesting that the proteolysis may be endogenous.
Multiple IGFBP-1 phosphoisoforms in AF samples are represented by several spots on 2-D immunobloting ( Fig. 1 c and d) . The crude AF showed one spot (# 1) towards pH 4.0 (20 kDa range) corresponding to the proteolyzed IGFBP-1 fragment. Additional 6 spots (#2-7) detected in the 30-35 kDa region corresponded to the intact IGFBP-1 phosphoisoforms. Similarly, 6 spots (# 4-9) were observed for the intact IGFBP-1 with the enriched AF sample (Fig. 1 d) . In addition, three distinct spots (# 1-3) in this sample were detected for the 20 kDa fragment (Fig. 1 d) possibly due to enrichment of the fragmented peptide. AKP treatment (Fig. 1 e) 
Total protein distribution in FFE fractions
The FFE procedure using a broad pH gradient provided resolution of proteins in the pH range approximately 3 to 10 (Fig. 2 a, i) . The DSE pH gradient includes a plateau of 10 fractions where the pH gradient is extremely shallow covering the pH range 5.0 to 5.1. This plateau enabled an efficient focusing of the abundant albumin at its pI value during separation. Total protein distribution in selected fractions from a total of96 fractions collected following FFE separation is shown 
Total IGFBP-1 distribution in FFE fractions
Total IGFBP-1 in individual FFE fractions E5 to F6 (3.5 mL/each) estimated by ELISA showed an overall 79% recovery as shown in Table 1 . The separation of total IGFBP-1 in FFE fractions was also confirmed qualitatively using immunoblot analysis. Since distribution of IGFBP-1 in FFE fractions was based on differences in pI values (pH 4.43 to 5.09), individual FFE fractions were considered representative of specific IGFBP-1 phosphoisoforms. IGFBP-1 phosphoisoforms in FFE fractions (Fig. 2 c) from acidic to basic pH (E5 to F6) represent potentially highly-phosphorylated to the less-phosphorylated isoforms (Lanes E6 and F6 are not shown). At the acidic end, fraction E5 was co-fractionated with the proteolytic 20 kDa fragment (Fig, 2c) . No attempts were made to evaluate the number of IGFBP-1 phosphoisoforms separated by FFE. An overall similarity could however be discerned with multiple IGFBP-1 phosphoisoforms separated using both gel-free FFE fractionation (Fig, 2c) and 2-D gel-based immunobloting of the unfractionated AF samples (Fig. 1d) .
Native immunoblot analysis of the crude AF sample (Fig. 3 a, Lane AF) showed five discernable variants of IGFBP-1 denoted by four closely associated intense bands and a fainter lower band.
Shown on the blot (Fig. 3 a) are also the FFE fractions G5 to E6. Native immunoblot analysis confirmed that the distribution of IGFBP-1 in FFE fractions (G5 to F6) was due to the relative state of IGFBP-1 phosphorylation. IGFBP-1 phosphoisoforms were detectable as two to three bands in each lane. The ascending shifts in bands from lower to higher pH with small differences in pH between the fractions were likely due to minute variability in the IGFBP-1 phosphorylation.
Multiple bands also represent the partial separation or overlapping IGFBP-1 phosphoisoforms.
Qualitatively, differences in the intensities of the bands in FFE fractions B6, C6 and E6 (fig 3 a) suggest predominance of some phosphoisoforms over the others.
IGF-I ligand blot analysis
Ligand blot analysis performed using crude AF in Fig 3 (b) demonstrated that IGFBP-1 was the major IGF binding protein. Additional faint bands (Lane AF) in the sample represent low levels of IGFBP-3 and some other IGFBPs in the crude AF. In FFE fractions G5 to E6, only IGFBP-1 was detected (Fig. 3 c) . The qualitative data in this study confirms that FFE separation resulted in highly selective enrichment of specifically IGFBP-1 and removal of other IGFBPs due to differences in pIs (29). Since no other IGF-I binding proteins were detectable under our experimental conditions, further purification was considered not to be necessary in the kinetic measurements of IGFBP-1.
IGF-I binding kinetics using Surface Plasmon Resonance (SPR) analysis
BIAcore data (Table 2) (Fig. 4 a) Figure 5a (i and ii) . The MS spectra with the observed b-and y-ion series allowed assignment of both the phosphopeptide sequence and the phosphorylation site. We did not obtain a spectrum which corresponds to a peptide with a singly phosphorylated site at Ser 98. The spectra for phosphorylated peptide with (pSer 119), 685.30 m/z, charge state +2; and (pSer 169), m/z 629.78, charge state +2 identified in the same fraction (C6) are shown in Fig. 5b (i and ii) .
LC-MS analyses were performed for selected fractions (F5 to D6) with equal concentration of total IGFBP-1 to estimate the peak intensity for each phosphorylated peptide. The differences in the recoveries of phosphopeptide upon TiO 2 enrichment and the LC-MS are summarized in Table 3 .
Because the intensities of each phosphopeptide are largely dependent on their sequence, the concentration of different phosphopeptide could not be directly compared with their intensities.
However, the intensities of the same phosphopeptide from different fractions were comparable and these intensities reflected the relative amount of the phosphopeptide in the specific fraction.
In order to determine the phosphorylation status of IGFBP-1 phosphoisoforms in individual FFE fractions, the phosphopeptide intensities in the corresponding fractions were matched with the affinity of IGFBP-1 for IGF-I (KDs, Table 2 ). While the IGF-I binding affinity across fractions F5 to D6 did not correlate with the intensities for pSer 101, pSer 98 and pSer 101 peptides, it linked well with the pSer 119 phosphopeptide, as shown in Table 3 . This data suggests that Ser 119 phosphorylation plays a significant role in modulating affinity of IGFBP-1 for IGF-I. A more precise quantitative analysis of these four phosphopeptides requires isotope labeling, which is the goal of a subsequent study.
IGFBP-1 phosphoisoforms in AF from FGR and control pregnancies
We applied 2-D immunobloting to distinguish IGFBP-1 phosphoisoforms in representative control and gestational age matched FGR samples (Fig. 6) . Although as expected, biological variability in IGFBP-1 isoforms was evident within each group, a lower number of spots corresponding to IGFBP-1 phosphoisoforms were obvious in the controls. In contrast, not only relatively greater numbers of phosphoisoforms were detected in the FGR samples, but also higher intensities of specific spots. Additionally, the acidic phosphoisoforms (towards pH 4) in FGR samples migrated further towards the acidic end with an upward shift due to a potentially greater phosphorylation (Fig.   6 ). Qualitatively, the differences observed between the control and FGR groups (Fig. 6 a and b) suggest further evaluation to determine if the variations are site specific and effect IGF-I affinity (30). In addition, this study provides a strong basis for use of FFE in studying the clinical and functional role of IGFBP-1 phosphorylation in FGR. Non-and phosphorylated isoforms of IGFBP-1 have been detected in AF using conventional approaches (14, 15, 32) . In this study, we introduced salting out (25) as a novel procedure for efficiently desalting and concentrating IGFBP-1 in a biofluid with abundant albumin. Rather than albumin depletion (28) or using ultra-filtration devices (33, 34) ammonium sulphate fractionation of AF (enriched AF) resulted in comparable yield. Using ammonium sulphate fractionated enriched AF, FFE fractionation effectively separated several functional IGFBP-1 phosphoisoforms with minute differences in pIs (35) . Subsequently, overlaps in IGFBP-1 phosphoisoforms were expected, but overall differently phosphorylated IGFBP-1 isoforms devoid of other IGF-binding proteins were separated. Direct assessment of IGF-I binding kinetics for IGFBP-1 phosphoisoforms was therefore feasible without further purification.
DISCUSSION
Multisite modifications on a protein constitute a complex regulatory mechanism in modulating protein functions in vivo (36) . In our study, we detected phosphorylation of IGFBP-1 at Ser 101, 119 and 169 residues as reported previously (37) M S A4 C4 E4 G4 A5 C5 E5 G5 A6 C6 E6 G6 A7 C7 E7 G7 A8 C8 E8 G8 A9 C9 E9 G9 A10 C10 
